With minimally invasive procedures to test lung cancer tumors, there often isn't enough tissue to undergo a full biomarker test, pointing toward the strength of liquid biopsies, explained Lynette M. Sholl, MD, chief of thoracic pathology at Brigham and Women's Hospital, Dana-Farber Cancer Institute, and associate professor at Harvard Medical School.
